These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9436641)

  • 61. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
    Lamharzi N; Halmos G; Jungwirth A; Schally AV
    Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
    Fekete M; Zalatnai A; Schally AV
    Cancer Lett; 1989 May; 45(2):87-91. PubMed ID: 2567204
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin].
    Schally AV
    An R Acad Nac Med (Madr); 2004; 121(3):493-500. PubMed ID: 15751842
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
    Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of ovariectomy, hypophysectomy and/or GnRH analog (HRF) administration on the cell proliferation of the MXT mouse hormone-dependent mammary tumor.
    de Launoit Y; Kiss R; Danguy A; Paridaens R
    Eur J Cancer Clin Oncol; 1987 Oct; 23(10):1443-50. PubMed ID: 3315693
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
    Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
    Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
    Schally AV; Srkalovic G; Szende B; Redding TW; Janaky T; Juhasz A; Korkut E; Cai RZ; Szepeshazi K; Radulovic S
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1061-7. PubMed ID: 1981009
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin.
    de Quijada MG; Redding TW; Coy DH; Torres-Aleman I; Schally AV
    Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3485-8. PubMed ID: 6134284
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone.
    Sharoni Y; Bosin E; Miinster A; Levy J; Schally AV
    Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1648-51. PubMed ID: 2646641
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
    Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
    Westphalen S; Kotulla G; Kaiser F; Krauss W; Werning G; Elsasser HP; Nagy A; Schulz KD; Grundker C; Schally AV; Emons G
    Int J Oncol; 2000 Nov; 17(5):1063-9. PubMed ID: 11029513
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.
    Reissmann T; Hilgard P; Harleman JH; Engel J; Comaru-Schally AM; Schally AV
    J Cancer Res Clin Oncol; 1992; 118(1):44-9. PubMed ID: 1530849
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
    Plonowski A; Schally AV; Nagy A; Groot K; Krupa M; Navone NM; Logothetis C
    Cancer Lett; 2002 Feb; 176(1):57-63. PubMed ID: 11790454
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Changes in the 32P incorporation in rat mammary tumor after chronic administration of LH-RH analogs.
    Cehovic G; Redding TW; Schally AV
    Med Oncol Tumor Pharmacother; 1985; 2(4):243-7. PubMed ID: 2935686
    [TBL] [Abstract][Full Text] [Related]  

  • 76. LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro.
    Szöke B; Horváth J; Halmos G; Rékási Z; Groot K; Nagy A; Schally AV
    Peptides; 1994; 15(2):359-66. PubMed ID: 8008640
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Westphal G; Halmos G; Engel JB
    Cancer Res; 2005 Jul; 65(13):5857-63. PubMed ID: 15994963
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T; Redding TW; Ben-David M; Schally AV
    Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.
    Popovics P; Schally AV; Szalontay L; Block NL; Rick FG
    Oncotarget; 2014 Jun; 5(12):4567-78. PubMed ID: 24994120
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
    BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.